Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track UTHR with free AI briefings, catalyst countdowns, and dilution alerts.

UTHR · UNITED THERAPEUTICS Corp

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$3.5B Cash on Hand
CF+ Cash Runway
Follow UTHR by email Get an email when UTHR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about UTHR, unsubscribe in one click. Privacy

📣 What UTHR Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Dinutuximab
FDA approved Mar 2015 · Unituxin
Neuroblastoma Phase 2 · NCT06450041 Recruiting
Treprostinil Pulmonary Arterial Hypertension Phase 4 · NCT05203510 Active not recruiting
Ralinepag PAH Phase 3 · NCT03683186 Enrolling by invitation
Inhaled treprostinil Pulmonary Hypertension Phase 3 · NCT03794583 Terminated
Universal Donor (UD) TGFβi NK Cells Neuroblastoma Phase 2 · NCT06450041 Recruiting
Irinotecan Neuroblastoma Phase 2 · NCT06450041 Recruiting
GGTA1 KO Thymokidney ESRD (End-Stage Renal Disease) Phase 1/2 · NCT07224763 Recruiting
Cytotoxic Chemotherapeutic Agent Neuroblastoma Phase 2 · NCT05421897 Active not recruiting
10 GE Xenokidney ESRD (End-Stage Renal Disease) Phase 1/2 · NCT06878560 Recruiting
Natural Killer Cell Neuroblastoma Phase 1 · NCT02573896 Active not recruiting

Also used in these trials (approved or third-party drugs, not UTHR's own candidates): Vorinostat, Temozolomide, Recombinant Granulocyte-Macrophage Colony-Stimulating Factor, Lenalidomide, Potassium Iodide, Sargramostim.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

UTHR holds $3.5B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when UTHR files for a raise →

👥 Who Owns UTHR

Insiders 0.2% Institutions (1224 holders) 99.8% Public and other holders 0%
HolderTypeShares% of sharesAs of
Vanguard Capital Management Institution (13G, 5%+) 2,278,348 5.35% 2026-03-31
Martine A Rothblatt
Chairperson & CEO, Director · +24,410 options
Insider 49,581 0.12% 2026-11-13
Paul A Mahon
EVP & GENERAL COUNSEL · +22,640 options
Insider 45,172 0.11% 2026-11-05
Nilda Mesa
Director · +6,430 options
Insider 5,580 0.01% 2026-09-14
Christopher Patusky
Director · +3,000 options
Insider 3,240 0.01% 2026-11-09

Share count 42,588,726 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full UTHR picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for UTHR and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.